Drug Trial Radar · NCT04382651
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jun 11, 2020
Primary completion
Jan 6, 2021
Study completion Apr 21, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
Conditions
- COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825Drug
MAS825 liquid solution for intravenous infusion
PlaceboOther
Placebo liquid solution for intravenous infusion
Standard of Care (SoC)Drug
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)Time frame: up to Day 15
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Chula Vista, California
Novartis Investigative Site
Glendale, California
Novartis Investigative Site
Irvine, California
Novartis Investigative Site
La Mesa, California
Novartis Investigative Site
Santa Monica, California
Novartis Investigative Site
Torrance, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Idaho Falls, Idaho
Novartis Investigative Site
Alexandria, Louisiana
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Lafayette, Louisiana
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Brooklyn, New York
Novartis Investigative Site
Asheville, North Carolina
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Bend, Oregon
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Mesquite, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.